Author:
Safonov Anton,Wang Shiyi,Gross Cary P.,Agarwal Divyansh,Bianchini Giampaolo,Pusztai Lajos,Hatzis Christos
Funder
National Center for Advancing Translational Sciences
Associazione Italiana per la Ricerca sul Cancro
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Scalo JF, Rascati KL (2014) Trends and issues in oncology costs. Expert Rev Pharmacoecon Outcomes Res 14(1):35–44. doi:
10.1586/14737167.2014.864561
2. Fund C (2008) Why not the best?: results from the National Scorecard on US Health System Performance 2008. Commonwealth Fund, New York
3. Woolf SH, Aron L (2013) U.S. Health in International perspective: shorter lives, poorer health. In: Woolf SH, Aron L (eds) The National academies collection: reports funded by National Institutes of Health. Institute of Medicine of the National Academies, Washington
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:
10.1056/NEJM200103153441101
5. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567. doi:
10.1038/nature14011
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献